Summary
Increased α2-macroglobulin (α2M) activity and concentration, and decreased antithrombin III (ATIII) plasma concentration are reported in diabetic subjects. In diabetes an inverse correlation between ATIII activity and blood glucose, HbA1. α2M activity and α2M concentration, and a direct correlation between both α2M concentration with blood glucose and HbA1 are found. Moreover, a direct correlation between α2M activity and α2M concentration fails. In both diabetic and normal subjects induced hyperglycemia increases α2M activity and α2M concentration reduces ATIII activity, while ATIII concentration is not affected. These data which show that hyperglycemia may increase α2M molecule levels while altering only the biological function of ATIII, provide evidence that hyperglycemia may decrease, directly, the biological function of some proteins and may condition the levels of some risk factors for the development of diabetic complications such as α2M.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abildgaard U., Lie M., Odegard O. R.: Antithrombin III (heparin co-factor) assay with a ‘new’ chromogenic substrates (S-2238 and Chromozym TH) — Thrombos. Res.11, 549, 1977.
Banerjee R. N., Sahni A. L., Kumar U., Arya M.: Antithrombin III deficiency in maturity onset diabetes mellitus and atherosclerosis — Thrombos. Diathes. Haemorrh. (Stuttg.)31, 339, 1974.
Brownlee M.: α2-macroglobulin and reduced basement membrane degradation in diabetes — Lanceti, 779, 1976.
Brownlee M., Vlassara H., Cerami A.: Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes — Diabetes33, 532, 1984.
Ceriello A., Dello Russo P., Zuccotti C., Florio A., Nazzaro S., Pietrantuono C., Rosato G. B.: Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation. A preliminary report — Thrombos. Haemostas.50, 633, 1983.
Ceriello A., Giugliano D., Dello Russo P., Tirelli A., Passariello N., Sgambato S.: Metabolic control may alter antithrombin III activity but not its plasma concentration in insulin-dependent diabetes. A possible role for non-enzymatic glycosylation — Diabet. Care.9, 32, 1986.
Ceriello A., Giugliano D., Quatraro A., Stante A., Consoli G., Dello Russo P., D’Onofrio F.: Daily rapid blood glucose variations may condition antithrombin III biological activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation — Diabète et Métabol.13, 16, 1987.
Ceriello A., Giugliano D., Quatraro A., Stante A., Consoli G., Dello Russo P., D’Onofrio F.: Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics — Haemostasis16, 458, 1986.
Ceriello A., Curcio F., Dello Russo P., Giugliano D.: Non-enzymatic glycosylation reduces antithrombin III activity — Thrombos. Haemostas.52, 363, 1984.
Ceriello A., Giugliano D., Quatraro A., Stante A., Consoli G., Dello Russo P., D’Onofrio F.: Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects — Diabetes36, 320, 1987.
Ganrot P. O.: Determination of α2-macroglobulin as trypsin-protein esterase — Clin. chim. Acta14, 493, 1966.
Harpel P. C., Rosemberg R. D.: α2-Macroglobulin and antithrombin heparin cofactor: modulators of hemostatic and inflammatory reactions. In:Spaet Th. H. (Ed.): Progress in hemostasis and thrombosis. Vol. 3. Grune & Stratton, New York-San Francisco-London, 1976; p. 145.
Jones R.: Fibrinopeptide A in diabetes mellitus: relation to blood glucose, fibrinogen disappearance and hemodynamic changes — Diabetes34, 836, 1985.
Juhan I., Vague Ph., Buonocore M., Moulin J. P., Jouve R., Vialettes B.: Abnormalities of erythrocyte deformability and platelet aggregation in insulin-dependent diabetics corrected by insulinin vivo andin vitro — Lanceti, 535, 1982.
Mallia A. K., Herfmanson G. T., Krohn R. J., Fujimoto E. K., Smith P. K.: Preparation and use of a boronic acid affinity support for separation and quantification of glycosylated hemoglobin — Analyt. Letters.14, 649, 1981.
Mancini G., Carbonara A. O., Heremans J. F.: Immunochemical quantitation of antigens by single radial immunodiffusion — Immunochemistry2, 235, 1965.
McLaren E,H., Cullen D. R., Brown M. J.: Coagulation abnormalities in diabetic coma before and 24 hours after treatment — Diabetologia17, 345, 1979.
Ney K. A., Pasqua J. J., Colley K. J., Guthrow C. E., Pizzo S. V.:In vitro preparation of non-enzymatically glucosylated human transferrin, α2-macroglobulin and fibrinogen with preservation of function — Diabetes34, 462, 1985.
Tsianos E. B., Stathakis N. E.: Soluble fibrin complex and fibrinogen heterogeneity in diabetes mellitus — Thrombos. Haemostas.44, 130, 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ceriello, A., Giugliano, D., Quatraro, A. et al. Increased alpha2-macroglobulin in diabetes: A hyperglycemia related phenomenon associated with reduced antithrombin III activity. Acta diabet. lat 26, 147–154 (1989). https://doi.org/10.1007/BF02581366
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02581366